Announcements Trials
Browse Landscape

Phase

Phase 1/2 4

Status

Active not recruiting 5Completed 4Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 41Lung Neoplasms 13Neoplasms 6Neoplasm Metastasis 4Thoracic Neoplasms 2Noonan Syndrome 2NSCLC 2Meningeal Carcinomatosis 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1T790M Positive NSCLC Patients 1Solid Tumor 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Renal Insufficiency 1Progression Free Survival 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer Metastatic 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Lung Diseases 1Locally Advanced or Metastatic EGFR T790M+ NSCLC 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × osimertinib × Clear all
NCT01802632 2026-04-20

AURA

AstraZeneca

Phase 1/2 Completed
603 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT02917993 2026-02-09

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Incyte Corporation

Phase 1/2 Completed
59 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Inhibition, Psychological, Lung Neoplasms, Neoplasm Metastasis

NCT04770688 2024-08-15

AUTOMAN

Shanghai Chest Hospital

Phase 1/2 Completed
25 enrolled
Thoracic

Adenocarcinoma of Lung, Neoplasm Metastasis

NCT02803203 2023-09-22

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
49 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡